Figure 3 | Modern Pathology

Figure 3

From: Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

Figure 3

Expression of pathobiological markers in germinal center B-cell-like (GCB) and activated B-cell-like (ABC) diffuse large B-cell lymphoma with or without Myc overexpression. In both GCB- and ABC-DLBCL, Myc overexpression was associated with significantly higher levels of p53 (a), MDM2 (b), Ki-67 (d), Bcl-6 (f), and FOXP1 (g), and a significantly lower level of c-Rel (k). In GCB-DLBCL only, Myc overexpression was associated with significantly higher levels of CD10 (e), pAKT (j), and CXCR4 (l). In ABC-DLBCL only, Myc overexpression was associated with significantly higher levels of Bcl-2 (c) and MUM1 (h) levels and a significantly lower level of BLIMP-1 (i). Mychigh, high Myc protein expression; Myclow, low Myc protein expression.

Back to article page